Clinical trial · Interventional
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in France. Their incidence increases mainly due to ultraviolet (UV) exposure and population ageing. Then from 1994 to 2006, the incidence of cSCC has increased by 300%. CSCCs typically manifests as a spectrum from a precursor actinic keratosis (AK) - possible spontaneous regression at this stage- to in situ cSCC invasive cSCC and finally metastatic cSCC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinomas | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
| Cutaneous Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Patients with actinic keratoses
- interventionNames
- Other: biopsy
- type
- EXPERIMENTAL
- label
- patients with squamous cell carcinoma in situ
- interventionNames
- Other: biopsy
- type
- EXPERIMENTAL
- label
- patients with squamous cell carcinomas
- interventionNames
- Other: biopsy
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Every patient with suspected lesion : * AK, * in situ cSCC, * infiltrative cSSC * cSCC with recurrent disease * cSCC with cutaneous metastases. * Patients 18 years of age or older, * Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic), * Patient able to sign a consent form, * Patient affiliated with a Social Security system. Exclusion Criteria: * Prior systemic treatment such as checkpoint inhibitors or chemotherapy. * Patients with cSCC or AK localized on visible zone of the face or folds
References
Publications (5)
- BACKGROUNDObre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015 Feb;59:167-81. doi: 10.1016/j.biocel.2014.12.008. Epub 2014 Dec 24. PMID 25542180
- BACKGROUNDHosseini M, Dousset L, Mahfouf W, Serrano-Sanchez M, Redonnet-Vernhet I, Mesli S, Kasraian Z, Obre E, Bonneu M, Claverol S, Vlaski M, Ivanovic Z, Rachidi W, Douki T, Taieb A, Bouzier-Sore AK, Rossignol R, Rezvani HR. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. Cell Rep. 2018 Jun 19;23(12):3621-3634. doi: 10.1016/j.celrep.2018.05.060. PMID 29925003
- BACKGROUNDHosseini M, Dousset L, Michon P, Mahfouf W, Muzotte E, Bergeron V, Bortolotto D, Rossignol R, Moisan F, Taieb A, Bouzier-Sore AK, Rezvani HR. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis. 2019 Sep 24;8(10):52. doi: 10.1038/s41389-019-0161-z. PMID 31551419
- BACKGROUNDMahfouf W, Hosseini M, Muzotte E, Serrano-Sanchez M, Dousset L, Moisan F, Rachidi W, Taieb A, Rudolf J, Rezvani HR. Loss of Epidermal HIF-1alpha Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J Invest Dermatol. 2019 Sep;139(9):2016-2028.e7. doi: 10.1016/j.jid.2019.01.035. Epub 2019 Mar 13. PMID 30878676
- RESULTDousset L, Khalife F, Chalopin-Fillot D, Dartigues B, Naji F, Mahfouf W, Muzotte E, Rousseau B, Amoedo N, Claverol S, Bondaz M, Beltzung F, Jullie ML, Vergier B, Taieb A, Favot-Laforge L, Rossignol R, Beylot-Barry M, Nikolski M, Rezvani HR. Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors. Br J Dermatol. 2025 Oct 17;193(5):936-947. doi: 10.1093/bjd/ljaf253. PMID 40577595